Tactile Systems Technology, Inc.
TCMDHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeTactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. Valued at $529.8M, TCMD is a small-cap name in its sector. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds.
Market Cap
$529.8M
Beta
0.82
P/E (TTM)
21.46
P/E (Fwd)
16.08
EPS (TTM)
$1.09
EPS (Fwd)
$1.46
ROE
11.9%
ROA
7.9%
Cash
$69.9M
Total Debt
$14.4M
Free CF
$14.5M
52W Change
55.9%
Annual Financials
Cash vs Debt
Where TCMD stands vs its 150-day and 200-day moving averages
As of the September 15, 2026 close, TCMD finished 13.99% below its 150-day moving average ($26.24) and 15.94% below its 200-day moving average ($26.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TCMD overbought or oversold?
At the September 15, 2026 close, TCMD's RSI(14) was 38.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $69.9M in cash comfortably exceeding the $14.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $14.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 11.9%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 7.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $246.8M (2022) to $329.5M (2025), reflecting a 34% increase over the period.
With cash comfortably exceeding debt, TCMD has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing TCMD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.